{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:56:49Z","timestamp":1783612609548,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40264-021-01120-9","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:53:24Z","timestamp":1635249204000},"page":"1365-1374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A\u00a0Retrospective Case Series"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-8538","authenticated-orcid":false,"given":"Samantha","family":"Cotter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Gada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajdeep","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Christopher","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Mundkur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"1120_CR1","unstructured":"Ketalar (ketamine hydrochloride) [package insert]. Chestnut Ridge: Par Pharmaceutical; 2020."},{"issue":"4","key":"1120_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351\u20134.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"1120_CR3","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1213\/01.ANE.0000086618.28845.9B","volume":"97","author":"G Hocking","year":"2003","unstructured":"Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003;97(6):1730\u20139.","journal-title":"Anesth Analg"},{"issue":"8","key":"1120_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856\u201364.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20133","key":"1120_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pain.2009.08.015","volume":"147","author":"RJ Schwartzman","year":"2009","unstructured":"Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009;147(1\u20133):107\u201315.","journal-title":"Pain"},{"issue":"3","key":"1120_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.pain.2009.06.023","volume":"145","author":"MJ Sigtermans","year":"2009","unstructured":"Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. 2009;145(3):304\u201311.","journal-title":"Pain"},{"issue":"7","key":"1120_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","volume":"174","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry. 2017;174(7):695\u20136.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"1120_CR8","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.4088\/JCP.17f11738","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):e852\u20137.","journal-title":"J Clin Psychiatry"},{"key":"1120_CR9","unstructured":"Spravato (esketamine) [prescribing information]. Titusville: Janssen Pharmaceuticals, Inc.; 2020."},{"issue":"4","key":"1120_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"G Sanacora","year":"2017","unstructured":"Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiat. 2017;74(4):399\u2013405.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"1120_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11916-018-0664-x","volume":"22","author":"J Zhao","year":"2018","unstructured":"Zhao J, Wang Y, Wang D. The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systemic review and meta-analysis. Curr Pain Headache Rep. 2018;22(2):12.","journal-title":"Curr Pain Headache Rep"},{"issue":"5","key":"1120_CR12","first-page":"521","volume":"43","author":"SP Cohen","year":"2018","unstructured":"Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521\u201346.","journal-title":"Reg Anesth Pain Med"},{"issue":"14","key":"1120_CR13","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1517\/14656566.2010.515978","volume":"11","author":"I Noppers","year":"2010","unstructured":"Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother. 2010;11(14):2417\u201329.","journal-title":"Expert Opin Pharmacother"},{"issue":"1\u20133","key":"1120_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jad.2012.10.015","volume":"147","author":"SM Szymkowicz","year":"2013","unstructured":"Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord. 2013;147(1\u20133):416\u201320.","journal-title":"J Affect Disord"},{"issue":"2","key":"1120_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jpainsymman.2015.06.002","volume":"50","author":"R Quibell","year":"2015","unstructured":"Quibell R, Fallon M, Mihalyo M, Twycross R, Wilcock A. Ketamine. J Pain Symptom Manag. 2015;50(2):268\u201378.","journal-title":"J Pain Symptom Manag"},{"issue":"9","key":"1120_CR16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jama.2017.10697","volume":"318","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson ST, Sanacora G. Considerations on the off-label use of ketamine as a treatment for mood disorders. JAMA. 2017;318(9):793\u20134.","journal-title":"JAMA"},{"issue":"1","key":"1120_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/ADM.0b013e3182399216","volume":"6","author":"E Gutkin","year":"2012","unstructured":"Gutkin E, Hussain SA, Kim SH. Ketamine-induced biliary dilatation: from Hong Kong to New York. J Addict Med. 2012;6(1):89\u201391.","journal-title":"J Addict Med"},{"issue":"1","key":"1120_CR18","first-page":"53","volume":"15","author":"SW Wong","year":"2009","unstructured":"Wong SW, Lee KF, Wong J, Ng WW, Cheung YS, Lai PB. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J. 2009;15(1):53\u20136.","journal-title":"Hong Kong Med J"},{"issue":"3","key":"1120_CR19","first-page":"e52","volume":"52","author":"RS Lo","year":"2011","unstructured":"Lo RS, Krishnamoorthy R, Freeman JG, Austin AS. Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singapore Med J. 2011;52(3):e52\u20135.","journal-title":"Singapore Med J"},{"issue":"1","key":"1120_CR20","first-page":"6","volume":"16","author":"SH Ng","year":"2010","unstructured":"Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J. 2010;16(1):6\u201311.","journal-title":"Hong Kong Med J"},{"issue":"8","key":"1120_CR21","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1097\/PEC.0000000000000502","volume":"33","author":"JW Wang","year":"2017","unstructured":"Wang JW, Kivovich V, Gordon L. Ketamine abuse syndrome: hepatobiliary and urinary pathology among adolescents in Flushing, NY. Pediatr Emerg Care. 2017;33(8):e24\u20136.","journal-title":"Pediatr Emerg Care"},{"issue":"6","key":"1120_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00261-014-0173-2","volume":"39","author":"WL Yu","year":"2014","unstructured":"Yu WL, Cho CC, Lung PF, et al. Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. Abdom Imaging. 2014;39(6):1241\u20136.","journal-title":"Abdom Imaging"},{"key":"1120_CR23","first-page":"612","volume":"10","author":"L Li","year":"2016","unstructured":"Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016;10:612.","journal-title":"Front Hum Neurosci"},{"key":"1120_CR24","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de S\u00e1nte. K\u00e9tamine: risque d\u2019atteintes h\u00e9patiques graves lors d\u2019utilisations prolong\u00e9es et\/ou \u00e0 doses \u00e9lev\u00e9es: lettre aux professionnels de sant\u00e9. Updated 2017. https:\/\/ansm.sante.fr\/S-informer\/Informations-de-securite-Lettres-aux-professionnels-de-sante\/Ketamine-risque-d-atteintes-hepatiques-graves-lors-d-utilisations-prolongees-et-ou-a-doses-elevees-Lettre-aux-professionnels-de-sante. Accessed 22 Jan 2021."},{"key":"1120_CR25","unstructured":"National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Ketamine: risk of severe liver damage with repeated and\/or prolonged use at high doses. Updated June 2017. https:\/\/www.npra.gov.my\/images\/Publications\/REAKSI_Drug_Safety_News\/2017\/REAKSI62017.pdf. Accessed 22 Jan 2021."},{"key":"1120_CR26","unstructured":"MedDRA MSSO. Introductory guide for Standardized MedDRA Queries (SMQs). Version 21.0. Updated March 2018. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_21_0_english.pdf. Accessed 22 Jan 2021."},{"key":"1120_CR27","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Severity grading in drug induced liver injury. Updated 4 May 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548241\/. Accessed 24 June 2021."},{"key":"1120_CR28","first-page":"1767","volume-title":"Current medical diagnosis and treatment","author":"Diana Nicoll","year":"2007","unstructured":"Nicoll, D. Appendix: therapeutic drug monitoring and laboratory reference ranges. In: McPhee S, Papadakis M, editors. Current medical diagnosis and treatment. 46th ed. Columbus: McGraw Hill; 2007. p. 1767\u201375.","edition":"46"},{"issue":"3","key":"1120_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1526-4637.2004.04043.x","volume":"5","author":"GE Correll","year":"2004","unstructured":"Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 2004;5(3):263\u201375.","journal-title":"Pain Med"},{"key":"1120_CR30","unstructured":"National Institute on Drug Abuse. Health consequences of drug misuse. Introduction. Updated June 9, 2020. https:\/\/www.drugabuse.gov\/drug-topics\/health-consequences-drug-misuse\/introduction. Accessed 22 Jan 2021."},{"key":"1120_CR31","unstructured":"World Health Organization (WHO)-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. Updated June 2013. https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment. Accessed 22 Jan 2021."},{"key":"1120_CR32","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Updated 21 January, 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/?report=classic. Accessed 22 Jan 2021."},{"issue":"3","key":"1120_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/flgastro-2013-100378","volume":"5","author":"R Bevan","year":"2014","unstructured":"Bevan R, Burke D. Ketamine as a possible cause of cirrhosis in a patient with chronic pain. Frontline Gastroenterol. 2014;5(3):208\u201310.","journal-title":"Frontline Gastroenterol."},{"key":"1120_CR34","unstructured":"Tofani CJ, Halegoua-DeMarzio D. BLOG: 58 year old female with acute liver injury related to IV ketamine treatment for migraines. Healio Gastroenterology. January 2016. https:\/\/www.healio.com\/news\/gastroenterology\/20160105\/blog-58-year-old-female-with-acute-liver-injury-related-to-intermittent-iv-ketamine-for-treatment. Accessed 22 Jan 2021."},{"key":"1120_CR35","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.14309\/00000434-201510001-00765","volume":"110","author":"C Tofani","year":"2015","unstructured":"Tofani C, Gandhi K, Halegoua-DeMarzio D. Acute liver injury related to intermittent intravenous ketamine for the treatment of migraines: 765. Am Coll Gastroenterol ACG. 2015;110:S334\u20135.","journal-title":"Am Coll Gastroenterol ACG."},{"issue":"7","key":"1120_CR36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1213\/XAA.0000000000000650","volume":"10","author":"NA Hewitt","year":"2018","unstructured":"Hewitt NA, Cox P. Recurrent subanesthetic ketamine infusions for complex regional pain syndrome leading to biliary dilation, jaundice, and cholangitis: a case report. A A Pract. 2018;10(7):168\u201370.","journal-title":"A A Pract."},{"issue":"4","key":"1120_CR37","first-page":"336","volume":"11","author":"Y Kato","year":"1995","unstructured":"Kato Y, Homma I, Ichiyanagi K. Postherpetic neuralgia. Clin J Pain. 1995;11(4):336\u20138.","journal-title":"Clin J Pain"},{"issue":"9","key":"1120_CR38","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.pain.2011.03.026","volume":"152","author":"IM Noppers","year":"2011","unstructured":"Noppers IM, Niesters M, Aarts LP, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011;152(9):2173\u20138.","journal-title":"Pain"},{"issue":"2","key":"1120_CR39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/hep.26459","volume":"58","author":"A Turkish","year":"2013","unstructured":"Turkish A, Luo JJ, Lefkowitch JH. Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis. Hepatology. 2013;58(2):825\u20137.","journal-title":"Hepatology"},{"issue":"10","key":"1120_CR40","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.cgh.2014.01.041","volume":"12","author":"GL Wong","year":"2014","unstructured":"Wong GL, Tam YH, Ng CF, et al. Liver injury is common among chronic abusers of ketamine. Clin Gastroenterol Hepatol. 2014;12(10):1759-62.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1120_CR41","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jhep.2021.02.007","volume":"74","author":"V Mallet","year":"2021","unstructured":"Mallet V, Bock K, Doumbe Mandengue P, Dufour N, et al. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol. 2021;74:1243\u20134. https:\/\/doi.org\/10.1016\/j.jhep.2021.02.007.","journal-title":"J Hepatol"},{"key":"1120_CR42","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Ketamine. Updated April 25, 2018. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548337\/. Accessed 22 Jan 2021."},{"issue":"9","key":"1120_CR43","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1177\/0960327112436404","volume":"31","author":"MS Wai","year":"2012","unstructured":"Wai MS, Chan WM, Zhang AQ, Wu Y, Yew DT. Long-term ketamine and ketamine plus alcohol treatments produced damages in liver and kidney. Hum Exp Toxicol. 2012;31(9):877\u201386.","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"1120_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2044.1980.tb03713.x","volume":"35","author":"JW Dundee","year":"1980","unstructured":"Dundee JW, Fee JP, Moore J, McIlroy PD, Wilson DB. Changes in serum enzyme levels following ketamine infusions. Anaesthesia. 1980;35(1):12\u20136.","journal-title":"Anaesthesia"},{"issue":"9","key":"1120_CR45","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.pain.2011.04.031","volume":"152","author":"JW Sear","year":"2011","unstructured":"Sear JW. Ketamine hepato-toxicity in chronic pain management: another example of unexpected toxicity or a predicted result from previous clinical and pre-clinical data? Pain. 2011;152(9):1946\u20137.","journal-title":"Pain"},{"issue":"2","key":"1120_CR46","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep.23696","volume":"52","author":"RJ Fontana","year":"2010","unstructured":"Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730\u201342.","journal-title":"Hepatology"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01120-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:11:10Z","timestamp":1744715470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01120-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01120-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"12 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Samantha Cotter, Jennie Wong, Neha Gada, Rajdeep Gill, S. Christopher Jones, Grace Chai, Daniel Foster, Mark Avigan, and Mallika Mundkur declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Samantha Cotter, Jennie Wong, Neha Gada, Rajdeep Gill, S. Christopher Jones, Grace Chai, Daniel Foster, Mark Avigan, and Mallika Mundkur. The first draft of the manuscript was written by Samantha Cotter and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}